Cargando…
Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with (177)Lu-DOTATATE
We report the impact of (177)Lu-DOTATATE treatment on abdominal pain, diarrhea, and flushing, symptoms that patients with advanced midgut neuroendocrine tumors often find burdensome. Methods: All patients enrolled in the international randomized phase 3 Neuroendocrine Tumors Therapy (NETTER-1) trial...
Autores principales: | Strosberg, Jonathan R., Srirajaskanthan, Rajaventhan, El-Haddad, Ghassan, Wolin, Edward M., Chasen, Beth A., Kulke, Matthew H., Bushnell, David L., Caplin, Martyn E., Baum, Richard P., Hendifar, Andrew E., Öberg, Kjell, Ruszniewski, Philippe, Santoro, Paola, Broberg, Per, Leeuwenkamp, Oscar R., Krenning, Eric P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Society of Nuclear Medicine
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612179/ https://www.ncbi.nlm.nih.gov/pubmed/33771903 http://dx.doi.org/10.2967/jnumed.120.258897 |
Ejemplares similares
-
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with (177)Lu-Dotatate: an analysis of the NETTER-1 study
por: Strosberg, Jonathan, et al.
Publicado: (2020) -
(177)Lutetium-Dotatate delays decline in quality of life in patients with midgut neuroendocrine tumors
por: Strosberg, Jonathan
Publicado: (2018) -
Lutetium Lu-177 Dotatate Flare Reaction
por: Salner, Andrew L., et al.
Publicado: (2020) -
Efficacy and safety of (177)Lu‑DOTATATE in patients with advanced pancreatic neuroendocrine tumours: data from the NETTER-R international, retrospective study
por: Clement, Dominique, et al.
Publicado: (2022) -
Use of [(177)Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study
por: Glover, Matthew, et al.
Publicado: (2021)